Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Acta Endocrinol (Buchar) ; 19(4): 463-470, 2023.
Article in English | MEDLINE | ID: mdl-38933255

ABSTRACT

Context: There are evidences that excessive production of reactive oxygen species is one of important abnormalities that contribute to development of chronic diabetic complications. Objective: To test the effect of intensive insulin therapy with analogues through the examining the level of oxidative stress parameters. Subjects and Methods: Comparison of data obtained by prospective analysis in 49 patients with T1DM was used, before and after six months of intensive insulin analog therapy. Results: The values of all three investigated parameters of oxidative stress malondialdehyde (MDA); xanthine oxidase (XO) and nitrates and nitrites (NOx) in our population with T1DM compared to the control (group of 42 voluntary blood donors) are statistically higher. The levels of antioxidant protection parameters compared to the control group also differ; the activities of catalase and glutathione peroxidase (GPx) are statistically higher in our population of T1DM patients compared to the control and superoxide dismutase (SOD) activities are statistically lower.The values of all three examined parameters of oxidative stress decrease after six months of intensive insulin analog therapy and were statistically lower after the therapy: for MDA p<0.001, for XO p<0.01 and for NOx p<0.05. The activities of catalase (p<0.001) and GPx (p<0.01) both decrease with therapy, while the activity of SOD is highest after the sixth month of therapy (p<0.001). Conclusion: In our patients with T1DM compared to the control the level of oxidative stress is significantly higher. Intensive insulin analog therapy with aspart and glargine promotes predominantly the improvement of oxidative stress, and in a less degree antioxidant protection.

2.
Neoplasma ; 66(1): 63-72, 2018 Dec 10.
Article in English | MEDLINE | ID: mdl-30509100

ABSTRACT

Pyruvate dehydrogenase kinase 1 (PDHK1) and carbonic anhydrase IX (CAIX) are some of the most hypoxia-inducible proteins associated with tumors, implicated in glucose metabolism and pH regulation, respectively. They both appear to be necessary for model tumor growth, and their high level of expression in human tumors predicts poor patient outcome. Another thing they have in common is that hypoxia not only induces their expression but also their enzymatic activity. This work therefore simultaneously targets these two hypoxia-inducible proteins either pharmacologically or genetically in vitro and in vivo, leading to decreased cancer cell survival and significantly slower model tumor growth. It also suggests that CAIX and PDHK1 are important for cells originating from a colorectal primary tumor, as well as from its metastasis. Moreover, our analysis reveals a unique relationship between these two HIF-1 target genes. In conclusion, the attributes of PDHK1 and CAIX predict them to be promising targets for the design of new, specific inhibitors that could negatively influence tumor cell proliferation and survival, or increase efficacy of standard treatment regimens, and at the same time avoid normal tissue toxicity.


Subject(s)
Carbonic Anhydrase IX/antagonists & inhibitors , Hypoxia , Neoplasms/drug therapy , Protein Serine-Threonine Kinases/antagonists & inhibitors , Carbonic Anhydrase IX/metabolism , Cell Line, Tumor , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Neoplasms/metabolism , Protein Serine-Threonine Kinases/metabolism , Pyruvate Dehydrogenase Acetyl-Transferring Kinase
3.
Bratisl Lek Listy ; 117(8): 433-5, 2016.
Article in English | MEDLINE | ID: mdl-27546693

ABSTRACT

INTRODUCTION: Metformin is the first-line oral hypoglycemic agent in the treatment of type 2 diabetes mellitus with a number of positive effects. The aim of the study was to determine the effect of metformin on TSH levels in euthyroid and hypothyroid newly diagnosed diabetes mellitus type 2 patients. MATERIAL AND METHODS: The study included 255 newly diagnosed diabetes mellitus type 2 drug naive patients, 170 euthyroid patinets, group A, 85 hypothiroid patients, group B, and 80 euthyroid DM type 2 patients on metformin therapy for more than 5 years, group C. Patients in groups A and B began metformin treatment with a dose of 2000 mg/day. We assessed baseline TSH, FT3, FT4 levels and TPOab, in groups A , B and C, and 6 months after initiation of metformin therapy in groups A and B. RESULTS: There were no differences in FT3 and FT4 levels after 6 months of metformin treatment in all groups. TSH level in Group A showed some reduction after 6 months of metformin therapy, not statistically significant. The only statistically significant change in Group A is the change of TSH level after 6 months in TPOAb positive patients. There was statiscically significant decrease in TSH level after 6 months in group B. There were no significant differences of basal TSH, FT3 and FT4 levels in groups A and B compared to group C. CONCLUSION: The results show that metformin has TSH lowering effect in patients with type 2 DM and hypothyreoidism, but also in euthyroid TPOab positive, levothyroxine naive patients. We have shown that the TSH lowering effect of metformin is not dependent on long term metformin therapy (Tab. 2, Ref. 18).


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Hypothyroidism/physiopathology , Metformin/administration & dosage , Thyroid Gland/drug effects , Thyroid Hormones/blood , Thyrotropin/blood , Adult , Aged , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Female , Humans , Hypoglycemic Agents/therapeutic use , Hypothyroidism/blood , Male , Metformin/adverse effects , Middle Aged , Thyroid Gland/metabolism , Thyroid Hormones/metabolism , Thyrotropin/metabolism , Thyroxine/blood , Thyroxine/metabolism , Treatment Outcome , Triiodothyronine/blood , Triiodothyronine/metabolism
4.
J BUON ; 17(1): 128-31, 2012.
Article in English | MEDLINE | ID: mdl-22517706

ABSTRACT

PURPOSE: Glomus tumors are rare tumors, highly vascular and typically radiosensitive. Therapeutic options include surgery, radiation therapy (RT), embolisation or any combination of them, but the appropriate treatment still remains a challenge. The purpose of this study was to report the results of local control of 7 patients with glomus tumors treated with surgery and external beam RT (EBRT). METHODS: All of the patients underwent primary surgery and then postoperative EBRT. Follow-up was calculated from the date of initiation of EBRT and ranged from 3 to 15 years (mean 7.14, median 6.2). The likelihood of local control was analysed using the Kaplan-Meier product limit method. We also analysed the average duration of response between two groups of patients with different doses of EBRT as well as the presence of acute and late EBRT complications. RESULTS: Local control was obtained in 6/7 (85.7%) patients. Moreover, local control was achieved in 3/4 (75%) patients with recurrent glomus tumors, while in patients with postoperative residual disease local control was obtained in 3/3 (100%) of them. Patients who received <50 Gy (n=2) had shorter average duration of response compared to patients who received >50 Gy (n=5; p=0.248). There were no severe treatment complications. CONCLUSION: Surgery and RT represent an appropriate treatment approach for advanced glomus tumors with acceptable complications.


Subject(s)
Glomus Tumor/therapy , Head and Neck Neoplasms/therapy , Adult , Aged , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Radiotherapy/adverse effects , Radiotherapy Dosage
5.
J BUON ; 16(2): 219-26, 2011.
Article in English | MEDLINE | ID: mdl-21766489

ABSTRACT

PURPOSE: Impaired IFNγ production in peripheral blood lymphocytes (PBL) and their subsets reflects immunosuppression and inadequate antitumor immune response in cancer patients. Decreased function of natural killer (NK) cells has not been investigated in breast cancer with respect to altered pSTAT signaling pathways. METHODS: PBL of breast cancer patients and healthy controls were analyzed for IFNγ and pSTAT1 expression and NK cell activity using flow cytometry and (51)Cr-release assay, respectively. The level of pSTAT1, 3 and 5 was investigated by Western blotting. RESULTS: Our results indicated that PBL and CD3(-) CD16(+) NK cells of patients had significantly lower level of IFNγ. The patients had a significantly decreased NK cell cytotoxicity compared to controls, with the decrease being dependent on the stage of disease. Positive correlation between IFNγ level in PBL and NK cytotoxicity in controls and patients was also shown. The PBL of patients, compared to controls, expressed lower level of pSTAT1, 3 and 5. The patients' T and NK cell subsets had lower pSTAT1 level. CONCLUSION: This study indicates that pSTAT1 in PBL of breast cancer patients could be a biomarker of decreased NK cell cytotoxicity and IFNγlevel that are associated with progression of this disease.


Subject(s)
Breast Neoplasms/blood , Breast Neoplasms/immunology , Carcinoma, Ductal, Breast/blood , Carcinoma, Ductal, Breast/immunology , Interferon-gamma/blood , Killer Cells, Natural/immunology , STAT Transcription Factors/blood , Adult , Aged , Blotting, Western , Bone Neoplasms/blood , Bone Neoplasms/immunology , Bone Neoplasms/secondary , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/secondary , Case-Control Studies , Cytotoxicity, Immunologic , Female , Flow Cytometry , Follow-Up Studies , Humans , Killer Cells, Natural/metabolism , Killer Cells, Natural/pathology , Liver Neoplasms/blood , Liver Neoplasms/immunology , Liver Neoplasms/secondary , Lung Neoplasms/blood , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Lymphatic Metastasis , Lymphocytes , Middle Aged , Neoplasm Staging , Phosphorylation , Signal Transduction
6.
Biomed Pharmacother ; 64(10): 663-71, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20800424

ABSTRACT

As IL-2 and IFN-α modulate NK cell activity it was of interest to investigate the expression of newly defined NK cell receptors and augmented NK cell activity in healthy individuals after cytokine in vitro treatment. Peripheral blood lymphocytes (PBL) obtained from 31 healthy volunteers treated for 18 h with 200 IU/ml IL-2 and 250 IU/ml IFN-α were evaluated for NK cell cytotoxicity. Expression of NKG2D, CD161, CD158a, CD158b receptors was analyzed on CD3⁻CD16+ NK cells, cytotoxic CD16(bright) and regulatory CD16(dim) subsets by FACS flow. The found induced significant in vitro enhancement of NK cell activity by both cytokines is supported by specific cytokine induction in PBL of pSTAT1 and pSTAT5, determined by Western blotting, as well as induction of IRF-1 transcription. Both cytokines induce significant up-regulation of NKG2D expression while only IFN-α induced significant up-regulation of CD161, with no alteration in KIR expression by either cytokine on CD3⁻CD16+ NK cells. Investigated cytokines did not induce change in NK cell bright and dim subset distribution. Moreover, we find that, not only cytokine receptor induction on the CD3⁻CD16+ NK cells, but also simultaneous increase in their percentage and/or density on CD16(bright) and CD16(dim) subsets, represent good indicators of receptor cytokine-susceptibility. As the role of NK cells has been shown in the loss of tolerance, infection and cancer, the data obtained in this study may be of help in NK cell profiling, by giving referent values of cytokine-induced novel NK cell receptor expression either in evaluation of these diseases or in immunomonitoring during cytokine immunotherapy.


Subject(s)
Cytotoxicity, Immunologic/drug effects , Interferon-alpha/pharmacology , Interleukin-2/pharmacology , Killer Cells, Natural/drug effects , NK Cell Lectin-Like Receptor Subfamily B/biosynthesis , NK Cell Lectin-Like Receptor Subfamily K/biosynthesis , Receptors, Natural Killer Cell/biosynthesis , Adult , Cell Line, Tumor , Female , Humans , K562 Cells , Killer Cells, Natural/metabolism , Lymphocytes/drug effects , Lymphocytes/metabolism , Male , Middle Aged , NK Cell Lectin-Like Receptor Subfamily B/blood , NK Cell Lectin-Like Receptor Subfamily B/genetics , NK Cell Lectin-Like Receptor Subfamily K/blood , NK Cell Lectin-Like Receptor Subfamily K/genetics , Receptors, KIR2DL1/antagonists & inhibitors , Receptors, KIR2DL1/genetics , Receptors, KIR2DL3/antagonists & inhibitors , Receptors, KIR2DL3/genetics , Receptors, Natural Killer Cell/blood , Receptors, Natural Killer Cell/genetics , Up-Regulation/genetics
7.
Bratisl Lek Listy ; 110(6): 335-9, 2009.
Article in English | MEDLINE | ID: mdl-19634573

ABSTRACT

OBJECTIVES: An impaired early phase of insulin secretion in the type 2 diabetes mellitus (DM) is very important for the postprandial hyperglycemia. The aim of the study was to compare the efficacy of metformin/repaglinid and metformin/glimepirid regimes in type 2 diabetics uncontrolled with metformin monotherapy. METHODS: Totally, 60 type 2 diabetics with haemoglobin A1c > or = 7.5% and 2000 mg of metformin monotherapy for at least three months were divided in the following groups: A-30 patients with metformin+repaglinid (2 mg for each meal) and B metformin+glimepirid (3 mg in the morning). Assessment of the regimes efficacy comprised of haemoglobin A1c, fasting blood glucose (FBG) and postprandial blood glucose (PBG). Assessment of the safety was performed on the basis of recorded hypoglycemia (<4.0 mmol/l). RESULTS: In both groups, FBG was significantly lower at the end of the study. In the group A it decreased from 9.03 +/- 1.00 to 7.32 +/- 0.65 (p < 0.001), in the group B from 8.94 +/- 1.01 to 7.23 +/- 0.70 (p < 0.001). There was no statistical difference between the groups. PBG was significantly lower after 12 weeks in both groups. CONCLUSION: Metformin/repaglinid is an efficient and safe therapeutic regime in the treatment of the type 2 DM that ensure a better control of PBG levels (Tab. 4, Ref. 18).


Subject(s)
Carbamates/administration & dosage , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/administration & dosage , Metformin/administration & dosage , Piperidines/administration & dosage , Sulfonylurea Compounds/administration & dosage , Blood Glucose/analysis , Diabetes Mellitus, Type 2/blood , Drug Therapy, Combination , Female , Glycated Hemoglobin/analysis , Humans , Male , Middle Aged
8.
J Endocrinol Invest ; 32(1): 23-7, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19337010

ABSTRACT

AIM: This 3-month study compared the effect on overall glycemic control of adding biphasic insulin aspart 30 (BIAsp30) and premixed human insulin 30/70 (BHI30) to metformin (met) in insulin-naïve, obese patients (30 males/20 females) with Type 2 diabetes (T2DM). MATERIAL/SUBJECTS: At baseline, patients had a mean age of 58.7 yr, glycated hemoglobin (HbA1c) 9.5%, and body mass index 34+/-2 kg/m2. Patients received either twice-daily BIAsp30 (no.=20) or twice-daily BHI30 (no.=30), and continued to receive maximal doses (2000 mg) of met for the duration of the study, but sulphonylurea oral antidiabetic drugs were discontinued. Primary efficacy endpoint was the change in HbA1c in both groups at study end. Safety endpoints included hypoglycemic episodes and weight gain. RESULTS: Both groups reduced HbA1c by end of trial: BIAsp30 + met by 2.5% [2.16-2.86%; 95% confidence interval (CI)]; BHI30 + met by 1.18% (0.98- 1.39%; 95% CI), giving a significantly better HbA1c reduction with BIAsp30 + met (1.33%; p<0.05). Post-prandial plasma glucose decreased in both groups, by 6.38 mmol/l in patients treated with BIAsp30 + met, and by 4.34 mmol/l in those treated with BHI30 + met (p<0.05). Fasting plasma glucose also decreased in both groups, with a slightly larger decrease seen in BIAsp30 patients than in BHI30 patients (7.36 mmol/l at end of study vs 7.82 mmol/l; p=ns). Subjects treated with BIAsp30 gained less weight than those receiving BHI30 (0.3+/-0.1 kg vs 1.2+/-0.4 kg). There was no significant difference in the frequency or number of hypoglycemic episodes between groups. CONCLUSIONS: Adding BIAsp30 to met in obese patients with T2DM results in better glycemic control and less weight gain than adding BHI30.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin/analogs & derivatives , Aged , Biphasic Insulins , Female , Glycated Hemoglobin/metabolism , Humans , Insulin/therapeutic use , Insulin Aspart , Insulin, Isophane , Male , Middle Aged
9.
Mol Ecol Resour ; 9(6): 1431-8, 2009 Nov.
Article in English | MEDLINE | ID: mdl-21564929

ABSTRACT

DNA barcoding has become a useful system for linking different biological life stages, and for identification of species within a known taxonomic framework. In this study, we generated mitochondrial DNA COI barcodes using adult specimens of all 22 species of the hoverfly genus Merodon (Diptera, Syrphidae) occurring on Lesvos island (Greece). The generated COI barcodes could well discriminate between all Merodon taxa of Lesvos, except for M. loewi and M. papillus that shared the same haplotype, despite their clear morphological differences. In addition, the barcodes revealed two cases of hitherto unknown morphologically cryptic species close to M. avidus and M. nigritarsis, respectively. Because only few successful rearings of immature stages of Merodon hoverflies are available, the larval host plant remains unknown for these phytophagous taxa. The obtained COI barcode library for the Merodon spp. of Lesvos will constitute a tool to link any unknown immature stages with already known species, and thus provide important life-history information and promise for ecological studies.

10.
Diabetes Obes Metab ; 2(4): 251-6, 2000 Aug.
Article in English | MEDLINE | ID: mdl-11225659

ABSTRACT

The principal metabolic effect of metformin-an oral antihyperglycaemic agent-is the improvement in the sensitivity of peripheral tissues and liver to insulin. This study examined the effect of metformin monotherapy on antioxidative defence system activity in erythrocytes and plasma in diabetic patients. We studied the effect of metformin treatment on the activities of Cu, Zn-superoxide dismutase (EC 1. 15. 1. 1.), catalase (EC 1. 11. 1. 6.) and glutathione peroxidase (EC 1. 11. 1. 9.) in relation to lipid peroxidation products and reduced glutathione level in plasma and erythrocytes. In this study we also examined erythrocytes' susceptibility to H2O2-induced oxidative stress during metformin therapy. Although metformin monotherapy ameliorated the imbalance between free radical-induced increase in lipid peroxidation (by reducing the MDA level in both erythrocytes and plasma) and decreased plasma and cellular antioxidant defences (by increasing the erythrocyte activities of Cu, Zn, SOD, catalase and GSH level) and decreased erythrocyte susceptibility to oxidative stress, it had negligible effect to scavenge Fe ion-induced free radical generation in a phospholipid-liposome system.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus/blood , Erythrocytes/enzymology , Hypoglycemic Agents/therapeutic use , Lipid Peroxidation/drug effects , Metformin/therapeutic use , Obesity , Blood Glucose/metabolism , C-Peptide/blood , Catalase/blood , Diabetes Mellitus, Type 2/enzymology , Erythrocytes/drug effects , Fructosamine/blood , Glutathione/blood , Glutathione Peroxidase/blood , Humans , Hydrogen Peroxide/toxicity , In Vitro Techniques , Middle Aged , Oxidative Stress/drug effects , Reference Values , Superoxide Dismutase/blood
13.
Srp Arh Celok Lek ; 124 Suppl 1: 115-6, 1996.
Article in Serbian | MEDLINE | ID: mdl-9102868

ABSTRACT

We evaluated the effect of PTH on blood pressure in haemodialysed patients. The correlation was found between systolic, diastolic pressure and PTH. The results have shown that PTH might have the influence on regulation of arterial blood pressure in these patients.


Subject(s)
Blood Pressure , Parathyroid Hormone/blood , Renal Dialysis , Adult , Aged , Blood Pressure/physiology , Female , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/therapy , Male , Middle Aged
14.
Srp Arh Celok Lek ; 124 Suppl 1: 153-5, 1996.
Article in Serbian | MEDLINE | ID: mdl-9102886

ABSTRACT

The estimation of CAPD efficacy presents a complex problem in the patients treated by this method. The most important parameters are: clinical indications, biochemical parameters, Kt/v, PCT, PET indexes, and others. Numerous factors may influence CAPD efficacy. Peritonitis, particularly the frequent episodes, significantly affects permeability and ultrafiltration capacity of the peritoneal membrane. The aim of this paper is to investigate the peritonitis incidence and its influence on some parameters of CAPD efficacy. Forty-four CAPD patients of both sexes, aged 55.7 +/- 13.5 yrs, dialysis duration 19.6 +/- 15 months, were studied. The influence of peritonitis incidence was studied using urea, creatinine, hemoglobin, hematocrit parameters and K t/v, PET indexes. Statistically significant low K t/v values were found in the patients who had four or more peritonitis episodes. Our results, as well as those in the literature, indicate that frequent peritonitis episodes significantly decrease the peritoneal membrane permeability.


Subject(s)
Peritoneal Dialysis, Continuous Ambulatory , Peritonitis/physiopathology , Adult , Aged , Creatinine/metabolism , Female , Humans , Kidney Failure, Chronic/physiopathology , Male , Peritonitis/etiology , Urea/metabolism
15.
Srp Arh Celok Lek ; 122 Suppl 1: 60-3, 1994.
Article in Serbian | MEDLINE | ID: mdl-18173190

ABSTRACT

Research in recent years has documented more exactly the genetic and immunopathogenetic basis of insulin-dependent diabetes mellitus. Also, in some genetically susceptible subjects, a triggering event activates both cellular and humoral immunity, with diminishing of b cellular mass. Early intervention to prevent diabetes development as well as to prevent microvascular complications is identification of individuals in whom autoimmunity has been activated. One of the non-specific tests is a screening test for the detection of circulating immune complexes /CIC/ by precipitating tests using polyethylene glycol it was performed in series of healthy, insulin-dependent and non-insulin dependent diabetic subjects. Highly increased precitability was seen in a great percentage of pathological sera. In spite of the non-specific method for immune complexes detection, positive results obtained by PEG method generally presumed that diabetes represent immune complex disease.


Subject(s)
Antigen-Antibody Complex/blood , Diabetes Mellitus, Type 1/immunology , Female , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...